ZEMBRACE SYMTOUCH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEMBRACE SYMTOUCH (ZEMBRACE SYMTOUCH).
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibition of trigeminal nerve transmission.
| Metabolism | Primarily metabolized by monoamine oxidase A (MAO-A) to an inactive indole acetic acid metabolite; minor metabolism by CYP450 enzymes. |
| Excretion | Primarily renal (approximately 80–90% as unchanged drug); fecal elimination is minor (<10%). |
| Half-life | Terminal elimination half-life is approximately 2.5 hours (range 2–3 hours) in healthy adults; prolonged in renal impairment. |
| Protein binding | Approximately 14% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Approximately 7.1 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Subcutaneous: 100% (absolute bioavailability via SC injection due to complete absorption). |
| Onset of Action | Subcutaneous injection: clinical effect observed within 2.5–3.5 hours post-dose. |
| Duration of Action | Duration of action is approximately 24 hours based on once-daily dosing; triptan effects may persist up to 24 hours. |
Subcutaneous administration of 140 mg/mL, 1 mL (140 mg) once daily, or 140 mg/mL, 2 mL (280 mg) once every 2 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients aged ≥65 years, no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZEMBRACE SYMTOUCH (ZEMBRACE SYMTOUCH).
| Breastfeeding | Sumatriptan is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 4.3 after subcutaneous administration. The relative infant dose is estimated to be about 3.5% of the maternal weight-adjusted dose. Limited data suggest that exposure to the nursing infant is low. However, due to potential for adverse effects (e.g., gastrointestinal disturbances, sleepiness), caution is advised. Consider the developmental and health benefits of breastfeeding, the mother's clinical need for sumatriptan, and any potential adverse effects on the breastfed infant. |
| Teratogenic Risk | ZEMBRACE SYMTOUCH (sumatriptan succinate) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, sumatriptan was associated with increased incidences of fetal malformations (including craniofacial and cardiovascular defects) and embryolethality at doses approximately 40 times the maximum recommended human dose. However, the relevance to human pregnancy is uncertain. First trimester exposure: Data from pregnancy registries and observational studies do not consistently suggest a major increase in the risk of birth defects, but a small increase in the risk of major congenital malformations cannot be excluded. Second and third trimesters: Potential for decreased uterine blood flow leading to fetal hypoxia; use only if potential benefit justifies potential risk. |
■ FDA Black Box Warning
Sumatriptan is contraindicated in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular disease due to risk of myocardial ischemia, infarction, and stroke.
| Serious Effects |
["Ischemic heart disease (angina pectoris, history of MI, documented silent ischemia)","Prinzmetal's angina/coronary artery vasospasm","Uncontrolled hypertension","Hemiplegic or basilar migraine","Within 24 hours of ergotamine-containing or ergot-type medications","Within 24 hours of another 5-HT1 agonist","Severe hepatic impairment","Concurrent MAO-A inhibitor therapy or within 2 weeks of discontinuation"]
| Precautions | ["Risk of myocardial ischemia, infarction, and arrhythmias","Cerebral and peripheral vascular events including stroke","Increased blood pressure","Serotonin syndrome, especially with concurrent serotonergic drugs","Medication overuse headache","Severe anaphylactic reactions","Ocular effects including angle-closure glaucoma","Use with caution in patients with hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of uterine hyperstimulation or decreased fetal heart rate variability due to potential vasoconstriction of uterine arteries. Assess fetal well-being by ultrasound and nonstress test as clinically indicated. Monitor maternal blood pressure and heart rate. In patients with cardiovascular risk factors, consider electrocardiogram monitoring. Observe for symptoms of serotonin syndrome when used with other serotonergic drugs. |
| Fertility Effects | There are no adequate data on the effect of sumatriptan on human fertility. In animal fertility studies, sumatriptan at doses up to 300-fold the human exposure did not impair fertility, but delayed implantation and reduced embryo survival were observed. The clinical relevance is unknown. |